Sort   by:  
 Page size 
UnknownNivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Not available
S-EPMC6075826 | biostudies-literature
UnknownCirculating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Not available
S-EPMC4430717 | biostudies-literature
UnknownPlasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Not available
S-EPMC6194135 | biostudies-literature
UnknownAssociation of FOXD1 variants with adverse pregnancy outcomes in mice and humans.
Not available
S-EPMC5090055 | biostudies-literature
UnknownInflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors.
Not available
S-EPMC6770345 | biostudies-literature
UnknownFive-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Not available
S-EPMC8078445 | biostudies-literature
UnknownTLR7 gain-of-function genetic variation causes human lupus.
Not available
S-EPMC9095492 | biostudies-literature
UnknownFour-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Not available
S-EPMC7193685 | biostudies-literature
UnknownDECTIN-1: A modifier protein in CTLA-4 haploinsufficiency.
Not available
S-EPMC10699772 | biostudies-literature
UnknownHuman Hsp60 with its mitochondrial import signal occurs in solution as heptamers and tetradecamers remarkably stable over a wide range of concentrations.
Not available
S-EPMC4022648 | biostudies-literature
Sort   by:  
 Page size